Stevanato Group Q2 2026 Earnings Call: Complete Transcript

Stevanato Group (NYSE: STVN ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. View the webcast at Summary Stevanato Group reported an 8% year-over-year revenue growth to $302 million for Q2 2026, driven by a 9% increase in the Biopharmaceutical and Diagnostic Solutions segment and a 16% increase in High Value Solutions revenue. The company completed the divestiture of its California-based subsidiary, Balda C. Brewer, to focus on high-value, integrated drug delivery systems, which is expected to be accretive to margins. Strong demand for injectable biologics, particularly GLP-1 therapies, is driving growth, with Alina's regulatory app...